Lilly Settles On Rolling Submission For Tirzepatide In Obesity
Executive Summary
Plan for rolling submission means US FDA filing of GIP/GLP1 agonist in obesity could be complete by April 2023, setting up possibility of late 2023 approval.
You may also be interested in...
Viking Emerges As Obesity Contender With Strong Phase II Readout
An analyst is calling data from Viking’s Phase II study of GLP-1/GIP agonist VK2735 best-in-class, even compared with approved therapies, with 13-week weight reductions as high as 14.7%.
Lilly’s Mounjaro Shows Strong Sales And Data As Firm Eyes Obesity Market
Excluding COVID-19 antibodies, the company said revenues for the quarter increased by 10% while volume increased by 18%, and sales of Mounjaro came in stronger than analysts anticipated.
Five Clinical Trial Hits Of 2022
Any given year sees a variety of clinical trials produce positive or negative results. But some of those trials are especially important either for moving a field forward or for a company’s overall development and commercial strategy. Here, Scrip looks at some of the more notable trial successes of the last year.